Blueprint promotes Philina Lee, expands Helen Ho’s role
Plus Clyburn leaving Merck & Co. and updates from Third Rock, BioTheryX, Ambys and more
Two weeks after picking COO Kate Haviland as CEO Jeff Albers’ successor, Blueprint Medicines Corp. (NASDAQ:BPMC) has promoted Philina Lee to chief commercial officer and expanded the role of SVP, Head of Corporate Development Helen Ho to include the CBO title. The moves make four the number of women executives promoted by Blueprint this month, including Christina Rossi who rose from chief commercial officer to COO. The changes come into effect April 4, when Lee and Ho will join Haviland and Rossi on the cancer and blood disorder company’s executive team and Albers will become executive chairman.
Frank Clyburn, EVP and president of human health at Merck & Co. Inc. (NYSE:MRK), will leave the company on Feb. 1 to become CEO and board member at International Flavors & Fragrances Inc., effective Feb. 14. Clyburn joined Merck in 2008 and managed multiple global pharmaceutical franchises, including diabetes, cardiovascular and women’s health. His replacement has yet to be announced. ...